Sunovion Statement regarding its Windsor, Nova Scotia Manufacturing Plant Closure

Sunovion Statement regarding its Windsor, Nova Scotia Manufacturing Plant Closure

Marlborough, Mass., December 5, 2012 – Sunovion Pharmaceuticals Inc. today announced that it will cease operations at its Windsor, Nova Scotia, Canada manufacturing facility in mid-2013. The decision to close the Windsor, Nova Scotia plant is critical to the company's business strategy to remain competitive and better align production capacity with anticipated product demand.

While this plant closure will regrettably result in a reduction of 32 jobs, the company has made transition arrangements for the affected employees.  In addition, this action will not affect Sunovion's Canadian sales operation or the ability to develop or sell our medications in Canada.

Sunovion remains committed to making all of our products available to the healthcare providers and the patients we serve in Canada, in the U.S. and across the globe.

About Sunovion Pharmaceuticals Inc. (Sunovion)
Sunovion is a leading pharmaceutical company dedicated to discovering, developing and commercializing therapeutic products that advance the science of medicine in areas of the central nervous system (CNS) and respiratory illnesses to improve the lives of patients and their families.  Sunovion's drug development program, together with its corporate development and licensing efforts, has yielded a portfolio of pharmaceutical products including LATUDA® (lurasidone HCl), LUNESTA® (eszopiclone), XOPENEX® (levalbuterol HCl) Inhalation Solution, XOPENEX HFA® (levalbuterol tartrate) inhalation aerosol, BROVANA® (arformoterol tartrate) inhalation solution, OMNARIS® (ciclesonide) nasal spray, ZETONNA® (ciclesonide) nasal aerosol and ALVESCO® (ciclesonide) HFA inhalation aerosol.

Sunovion, an indirect, wholly-owned subsidiary of Dainippon Sumitomo Pharma Co., Ltd., is headquartered in Marlborough, Mass.  More information about Sunovion Pharmaceuticals Inc. is available at